# Title

 Food and Drugs. PART 809â€”IN VITRO DIAGNOSTIC PRODUCTS FOR HUMAN USE


# ID

 CFR-2018-title21-vol8.Pt. 809


# Structured Analysis Summary

| Type        | Values                                                                                                                                                               |
|:------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Constraints | ['within', 'more than', 'highest', 'before', 'prior to']                                                                                                             |
| Condition   | ['unless', 'not subject to', 'where', 'subject to', 'provided that', 'when', 'if']                                                                                   |
| Entities    | ['U.S. Pharmacopeia', 'Vitro', 'Puerto Rico', 'Explain', 'Food', 'Indicate', 'English', 'Veterans Affairs', 'Data', 'Include', 'Describe', 'Washington, DC', 'List'] |


# Structured Analysis With Context

 


## Constraints

| Constraints   | Context                                                                                                                                  |
|:--------------|:-----------------------------------------------------------------------------------------------------------------------------------------|
| within        | submitted under &#167;&#8201;809.10(c) that are shown to fall within the exemption established in &#167;&#8201;20.61 of this chapter     |
| before        | products requiring manipulation, such as reconstitution and/or mixing before use, appropriate storage instructions shall be provided for |
| more than     | If  more than a single determination may be performed using the                                                                          |
| within        | bear all such information and which are packaged within an outer container from which they are removed                                   |
| before        | products requiring manipulation, such as reconstitution and/or mixing before use, appropriate storage instructions shall be provided for |
| within        | reaction material to be measured and the time within which it shall be measured to assure accurate                                       |
| highest       | of the range of calibration should include the highest  and the lowest values measurable by the procedure.                               |
| prior to      | product being shipped or delivered for product testing prior to full commercial marketing (for example, for use on                       |
| within        | bear all such information, and which are packaged within an outer container from which they are removed                                  |
| within        | bear all such information, and which are packaged within an outer container from which they are removed                                  |
| within        | for the device and the labeling on or within the package containing the device bears a prominent                                         |
| within        | for the device and the labeling on or within the package containing the device bears a prominent                                         |


## Condition

| Condition      | Context                                                                                                                            |
|:---------------|:-----------------------------------------------------------------------------------------------------------------------------------|
| subject to     | (the act), and may also be biological products subject to  section 351 of the Public Health Service Act.                           |
| when           | A class may be further divided into subclasses  when  appropriate.                                                                 |
| where          | diagnostic product shall state the following information, except where such information is not applicable, or as otherwise         |
| unless         | shall not be considered to be complied with unless such word, statement, or other information also appears                         |
| if             | also appears on the outside container or wrapper, if any there be, of the retail package of                                        |
| if             | also appears on the outside container or wrapper, if any there be, of the retail package of                                        |
| if             | of the established name (common or usual name), if any, and quantity, proportion or concentration of each                          |
| if             | permit tracing the identity of the individual units. if                                                                            |
| if             | should bear the same lot or control number, if  appropriate, or other suitable un                                                  |
| where          | in the format and order specified below, except where such information is not applicable, or as specified                          |
| if             | and established name, i.e., common or usual name, if  any.                                                                         |
| if             | Explain concisely, with chemical reactions and techniques involved,  if  applicable.                                               |
| if             | of the established name (common or usual name), if any, and quantity, proportion or concentration or each                          |
| where          | or more sensitive, is indicated in all cases where certain results are obtained, the need for the                                  |
| provided that  | and from a standard promulgated under part 861 provided that the following conditions are met: (1) In the                          |
| subject to     | of a shipment or delivery for an investigation subject to part 812, if there has been compliance with                              |
| if             | delivery for an investigation subject to part 812, if there has been compliance with part 812; or                                  |
| not subject to | shipment or delivery for an investigation that is not subject to part 812 (see &#167;&#8201;812.2(c)), if the following conditions |
| if             | delivery for an investigation subject to part 812, if there has been compliance with part 812; or                                  |
| if             | directions for use required by &#167;&#8201;809.10(a) and (b), if  their labeling meets the requirements of this paragraph.        |
| if             | name and established name (common or usual name), if  any, of the reagent.                                                         |
| if             | of the established name (common or usual name), if any, and quantity, proportion or concentration of the                           |
| where          | reagent derived from biological material, the source and where  applicable a measure of its activity.                              |
| if             | describing the product, its composition, and physical characteristics if  necessary for its proper use.                            |
| if             | (e)(1) The labeling for analyte spec if ic reagents (e.g., monoclonal antibodies, deoxyribonucleic acid (DNA)                      |
| if             | (e)(1) The labeling for analyte spec if ic reagents (e.g., monoclonal antibodies, deoxyribonucleic acid (DNA)                      |
| where          | reagent derived from biological material, the source and where  applicable, a measure of its activity.                             |
| if             | as how to contact a trained health professional if additional information on interpretation of test results from                   |
| where          | solely in Puerto Rico or in a Territory where the predominant language is one other than English,                                  |
| where          | solely in Puerto Rico or in a Territory where the predominant language is one other than English,                                  |
| where          | that is transparent, (i.e., open to public scrutiny), where  the participation is balanced,                                        |
| where          | that is transparent, (i.e., open to public scrutiny), where  the participation is balanced,                                        |
| where          | that is transparent, (i.e., open to public scrutiny), where  the participation is balanced,                                        |
| where          | that is transparent, (i.e., open to public scrutiny), where  the participation is balanced,                                        |
| if             | title of the symbol and its reference number, if any, in the standard; and (D) The meaning                                         |
| if             | title of the symbol and its reference number, if any, in the standard; and (D) The meaning                                         |
| if             | and not explicitly required by statute, for spec if ied lots, batches, or other units of an                                        |
| subject to     | diagnostic product for human use that would be subject to the exception or alternative; (ii) Identify the labeling                 |
| subject to     | diagnostic product for human use that would be subject to the exception or alternative; (ii) Identify the labeling                 |
| when           | Center Director may impose appropriate conditions or safeguards when granting such an exception or alternative under this          |
| subject to     | to ensure that the labeling of the product subject to the exception or alternative includes the information necessary              |
| if             | section satisfies the provisions relating to premarket not if ication submissions under &#167;&#8201;807.81(a)(3) of this chapter. |
| if             | found in part 820 of this chapter and, if  applicable, with &#167;&#8201;610.44 of this chapter.                                   |
| subject to     | Federal Food, Drugs, and Cosmetic Act (the act) subject to  the restrictions set forth in this section.                            |
| when           | This statement would not be applicable or required when test results are generated using the test that                             |
| when           | through (f) of this section do not apply when reagents that otherwise meet the analyte specific reagent                            |
| subject to     | restricted devices under section 520(e) of the Act subject to  the restrictions set forth in this section.                         |


## Entities

| Entities          | Context                                                                                                                                 |
|:------------------|:----------------------------------------------------------------------------------------------------------------------------------------|
| Food              | Food  and Drugs.                                                                                                                        |
| Data              | Data and information submitted under &#167;&#8201;809.10(c) that are shown                                                              |
| Vitro             | by the product; and a statement &#8220;For In Vitro Diagnostic Use&#8221; and any other limiting statements appropriate                 |
| Explain           | Explain concisely, with chemical reactions and techniques involved, if                                                                  |
| Vitro             | by the product; and a statement &#8220;For In Vitro Diagnostic Use&#8221; and any other limiting statements appropriate                 |
| List              | List any points that may be useful in improving                                                                                         |
| Include           | Include  such details as sizes, numbers, types, and quality.                                                                            |
| Describe          | Describe preparation of reference sample(s), use of blanks, preparation                                                                 |
| Indicate          | Indicate how the range(s) was established and identify the                                                                              |
| U.S. Pharmacopeia | e.g., those established by the American Chemical Society, U.S. Pharmacopeia , National Formulary, National Research Council.            |
| U.S. Pharmacopeia | e.g., those established by the American Chemical Society, U.S. Pharmacopeia , National Formulary, and National Research Council.        |
| English           | of the symbols glossary that is written in English or, in the case of articles distributed solely                                       |
| Puerto Rico       | in the case of articles distributed solely in Puerto Rico or in a Territory where the predominant language                              |
| English           | of the symbols glossary that is written in English or, in the case of articles distributed solely                                       |
| English           | of the symbols glossary that is written in English or, in the case of articles distributed solely                                       |
| Puerto Rico       | in the case of articles distributed solely in Puerto Rico or in a Territory where the predominant language                              |
| English           | of the symbols glossary that is written in English or, in the case of articles distributed solely                                       |
| Explain           | subject of the exception or alternative request; (iii) Explain why compliance with such labeling provision(s) could adversely           |
| Veterans Affairs  | under VHA Directive 1106 (available from Department of Veterans Affairs , Veterans Health Administration, Washington, DC 20420); and    |
| Washington, DC    | from Department of Veterans Affairs, Veterans Health Administration, Washington, DC 20420); and (3) Organizations that use the reagents |
| Food              | Food and Drug Administration.&#8221; This statement would not be                                                                        |


